POSC7 Work Productivity and Activity Impairment for Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 AND CIMPASI-2)
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.153
https://www.valueinhealthjournal.com/article/S1098-3015(21)01948-3/fulltext
Title :
POSC7 Work Productivity and Activity Impairment for Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 AND CIMPASI-2)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01948-3&doi=10.1016/j.jval.2021.11.153
First page :
Section Title :
Open access? :
No
Section Order :
10922